Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
| Table 1 Assignment of probable IFNL3 phenotypes based on genotypes |
| Table 2 Recommendations for use of PEG-IFN-α–containing regimens based on IFNL3 genotype |
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014)
Tables included in the supplement:
| Supplemental Table S1. Genes associated with HCV treatment response |
| Supplemental Table S2. Frequencies of genotypes/alleles in major race/ethnic groups |
| Supplemental Table S3. Frequency of genotypes/alleles by individual publications for rs12979860 |
| Supplemental Table S4. Evidence linking genotype with phenotype |
Additional resources applicable to this guideline:
Drug resource mapping